Jacobio Pharmaceuticals Group (HKG:1167) said the European Medicines Agency granted the orphan drug designation to its cancer drug, according to a Monday filing with the Hong Kong bourse.
JAB-21822, KRAS G12C inhibitor Glecirasib, can be used in treating several cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, and in combination with cetuximab in colorectal cancer, the filing said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。